ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AKBA vs KRRO // NET PROFIT MARGIN

Akebia Therapeutics Inc. (NASDAQ) VS. Korro Bio Inc. (NASDAQ) • 15-METRIC TALLY: AKBA 4 — KRRO 3
▲ NET PROFIT MARGIN LEADER: AKBA
net-margins
-2.20%
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKBA VS. KRRO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AKBA KRRO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 83.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 AKBA /roic <GO>
EV/EBITDA & P/E Valuation 4.3x — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin 9.90% -60.00% +69.90 AKBA /operating-margins <GO>
Net Profit Margin ACTIVE -2.20% -60.00% +57.80 AKBA /net-margins <GO>
Revenue Growth (YoY) 47.50% 180.00% -132.50 KRRO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 AKBA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.2 71.4 -26.20 KRRO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $195.8M $210.8M -$15.0M KRRO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AKBA REV KRRO REV AKBA GROSS % KRRO GROSS % AKBA FCF KRRO FCF
FY 2025 $236.2M $6.4M 83.3% — $67.7M -$79.1M
FY 2024 $160.2M $2.3M 60.6% — -$40.7M -$78.0M
FY 2023 $194.6M $236.7M — — -$23.4M -$67.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKBA // BETA —
KRRO // BETA —